Sensorion Appoints Fred Chereau as Chief Executive Officer
Fred Chereau brings extensive leadership experience across the biotechnology and pharmaceutical industries, with deep expertise in gene therapy and company building, driven by a lifelong commitment to patients with rare diseases.
Fred joins from Alexion – AstraZeneca Rare Disease, where he served as Senior Vice President, Strategy and Business Development, following his tenure as President and CEO of LogicBio Therapeutics, which was acquired by Alexion in 2022.
Amit Munshi will continue as Chairman of the Board of Directors, having served as Interim Chief Executive Officer since February 2026.
Regulatory News:
